HLVX Stock Overview
A clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
HilleVax, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.86 |
| 52 Week High | US$20.22 |
| 52 Week Low | US$1.55 |
| Beta | 0.81 |
| 1 Month Change | 0% |
| 3 Month Change | 3.33% |
| 1 Year Change | -87.71% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -90.26% |
Recent News & Updates
Shareholder Returns
| HLVX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -4.6% | -3.3% | -2.2% |
| 1Y | -87.7% | -1.9% | 23.9% |
Return vs Industry: HLVX underperformed the US Biotechs industry which returned -2.6% over the past year.
Return vs Market: HLVX underperformed the US Market which returned 23.4% over the past year.
Price Volatility
| HLVX volatility | |
|---|---|
| HLVX Average Weekly Movement | 5.1% |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 17.0% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: HLVX has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: HLVX's weekly volatility has decreased from 15% to 5% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2019 | 90 | Rob Hershberg | www.hillevax.com |
HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc. and changed its name to HilleVax, Inc. in February 2021.
HilleVax, Inc. Fundamentals Summary
| HLVX fundamental statistics | |
|---|---|
| Market cap | US$89.72m |
| Earnings (TTM) | -US$150.28m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.6x
P/E RatioIs HLVX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HLVX income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$150.28m |
| Earnings | -US$150.28m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.12 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did HLVX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/23 05:08 |
| End of Day Share Price | 2024/12/23 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
HilleVax, Inc. is covered by 5 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Seamus Fernandez | Guggenheim Securities, LLC |
| Matthew Caufield | H.C. Wainwright & Co. |
| Eric Joseph | J.P. Morgan |